Depression therapeutics market seen reaching $17.14 billion by 2030

The global depression therapeutics market is projected to grow from $13.51 billion in 2026 to $17.14 billion by 2030, according to The Business Research Company. Rising depression prevalence, broader treatment access and demand for tailored care are driving growth across North America and fast-expanding Asia-Pacific.

Why it matters: - The depression therapeutics market is expanding as more people seek treatment for depressive disorders. - The market's growth reflects rising mental health spending, broader access to psychiatric care and growing acceptance of antidepressant medications. - The forecast points to stronger demand for rapid-acting drugs, combination therapies and treatments for resistant depression.

What happened: - The Business Research Company published its Depression Therapeutics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Sept. 9, 2026. - The report projects the market will rise from $12.76 billion in 2025 to $13.51 billion in 2026. - The same report forecasts the market will reach $17.14 billion by 2030. - The report uses a 5.9% CAGR for the 2025-2026 period and a 6.1% CAGR through 2030. - The report says North America was the largest regional market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - Depression therapeutics includes pharmaceutical and non-pharmacological treatments used to reduce depressive symptoms and improve daily functioning. - The report links market growth to a rising prevalence of depressive disorders, greater awareness of mental health issues and expanded psychiatric healthcare services. - The report also cites advances in depression diagnosis and a stronger regulatory push for new therapies. - Emerging trends include rapid-acting antidepressants, combination treatment approaches, personalized medication selection and targeted care for treatment-resistant depression. - The report says the market covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - More information is available through a free sample request. - The full report is also available online.

Between the lines: - The growth outlook suggests depression care is shifting from broad, one-size-fits-all treatment toward more specialized and faster-acting options. - The report's regional split points to mature demand in North America and stronger upside in markets where access and awareness are still improving. - The added analytics in the 2026 edition signal that buyers want more than market size estimates; they want segment-level guidance and forecasting tools.

What's next: - The report expects continued growth in antidepressant pipelines and more emphasis on early intervention and prevention. - The Asia-Pacific market is positioned to outpace other regions as healthcare infrastructure and mental health awareness expand. - The company is offering expert contact details and social channels for follow-up on the report.